Healthcare / Medical DevicesNasdaqCM
$210.84
-7.29 (-3.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $56.9M · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
61/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
24.0x
↑EV/EBITDA
16.0x
↑ROE
16.1%
↑Gross Margin
28.3%
↓Debt/Equity
0.36
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+11.9%
FCF CAGR
—
FCF margin
13.1%
FCF / Net income
1.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $602.8M · net income $68.3M · FCF $79.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $602.8M | $602.8M | $504.4M | $400.1M | $353.8M | — | — | — | — | $147.8M | $146.1M | $138.8M | $139.3M | $139.2M | $131.0M | $127.2M | $120.8M | $99.2M |
| Net Income | $68.3M | $68.3M | $59.0M | $44.9M | $41.8M | $15.9M | $13.4M | $19.8M | $14.3M | $9.2M | $8.0M | $7.6M | $7.6M | $11.3M | $10.9M | $10.8M | $9.4M | $6.0M |
| EBITDA | $111.5M | $111.5M | $95.8M | $69.0M | $67.4M | $29.6M | $25.0M | $32.9M | $27.4M | $17.3M | $17.9M | $16.6M | $15.9M | $21.5M | $19.6M | $18.5M | $17.5M | $11.1M |
| EPS | 8.75 | 8.75 | 7.58 | 5.83 | 5.45 | 2.09 | 1.77 | 2.63 | 1.93 | 1.26 | 1.10 | 1.05 | 1.05 | 1.59 | 1.55 | 1.48 | 1.37 | 0.94 |
| Gross Margin | 28.3% | 28.3% | 29.1% | 28.1% | 25.5% | — | — | — | — | 24.0% | 23.7% | 27.0% | 26.5% | 29.5% | 29.3% | 28.5% | 28.7% | 26.9% |
| Operating Margin | 15.4% | 15.4% | 16.7% | 15.3% | 12.6% | — | — | — | — | 7.9% | 8.4% | 8.4% | 8.3% | 12.5% | 12.7% | 12.4% | 11.9% | 8.3% |
| Net Margin | 11.3% | 11.3% | 11.7% | 11.2% | 11.8% | — | — | — | — | 6.2% | 5.5% | 5.5% | 5.4% | 8.1% | 8.3% | 8.5% | 7.8% | 6.0% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.36 | 0.36 | 0.60 | 0.16 | 0.29 | 0.37 | 0.00 | — | 0.16 | — | 0.01 | 0.01 | 0.02 | 0.03 | 0.11 | 0.09 | 0.14 | — |
| Current Ratio | 2.91 | 2.91 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $79.0M | $79.0M | $56.9M | $30.8M | $4.0M | $8.9M | $20.7M | $25.5M | $15.9M | $7.1M | $2.1M | $-3.2M | — | — | — | — | — | — |
| Returns | ||||||||||||||||||
| ROE | 16.1% | 16.1% | 17.2% | 15.7% | 17.6% | 8.2% | 7.6% | 12.2% | 10.2% | 7.4% | 7.0% | 7.3% | 8.0% | 13.2% | 14.9% | 17.6% | 18.9% | — |
| Valuation | ||||||||||||||||||
| P/E | 23.99 | 23.99 | 32.20 | 27.34 | 21.29 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 15.97 | 15.97 | 21.85 | 18.39 | 14.15 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 3.88 | 3.88 | 5.54 | 4.29 | 3.74 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 19.5% | 19.5% | 26.1% | 13.1% | — | — | — | — | — | 1.2% | 5.2% | -0.3% | 0.1% | 6.3% | 2.9% | 5.4% | 21.7% | — |
| EPS Growth | 15.4% | 15.4% | 30.0% | 7.0% | — | 18.1% | -32.7% | 36.3% | 53.2% | 14.5% | 4.8% | 0.0% | -34.0% | 2.6% | 4.7% | 8.0% | 45.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
28.8%
EPS terminal req.
$18.71
Spread vs growth
-13.4%
5Y implied EPS CAGR
20.9%
EPS terminal req.
$22.64
Spread vs growth
-5.5%
10Y implied EPS CAGR
15.3%
EPS terminal req.
$36.46
Spread vs growth
0.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.2%
Start / end P/E
30.6x → 24.1x
EPS bridge
7.58 → 8.75
Residual
-3.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.